CSIMarket Company Name, Ticker, Industry, else..
 
Intellia Therapeutics Inc   (NASDAQ: NTLA)
 
Price: $12.6300 $-0.11 -0.863%
Day's High: $12.890000343322754 Week Perf: -0.43 %
Day's Low: $ 12.43 30 Day Perf: 5.78 %
Volume (M): 1,608,435 52 Wk High: $ 28.25
Volume (M$): $ 0 52 Wk Avg: $13.42
Open: $12.83 52 Wk Low: $7.95



 Market Capitalization (Millions $) 1,686
 Shares Outstanding (Millions) 133
 Employees 377
 Revenues (TTM) (Millions $) 60
 Net Income (TTM) (Millions $) -400
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) 2

Business Description


Intellia Therapeutics Inc is a biotechnology company that focuses on developing therapeutic products based on the revolutionary CRISPR gene editing technology. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Intellia aims to utilize CRISPR technology to develop potential cures for genetic diseases by editing and correcting specific genes within the human body. They are also involved in precision oncology, where they aim to develop targeted therapies for various types of cancers. Intellia Therapeutics is known for its innovative research and collaboration with other leading institutions in the field of gene editing.


   Company Address: 40 Erie Street Cambridge 2139 MA
   Company Phone Number: 285-6200   Stock Exchange / Ticker: NASDAQ NTLA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CLDX        0.08% 
BEAM   -12.13%    
LENZ        5.09% 
MXCT   -1.55%    
OABI   -3.31%    
TNGX   -0.83%    
• View Complete Report
   



Clinical Study

Long-Term Insights from the Phase 1 Trial of Nexiguran Ziclumeran in Treating Hereditary ATTR Amyloidosis Data Presen...

Published Mon, Sep 22 2025 11:57 AM UTC

Intellia Therapeutics Inc. is set to present compelling longer-term data from its ongoing Phase 1 clinical trial of Nexiguran Ziclumeran (nex-z), an innovative therapeutic approach for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). This significant update will be unveiled at the 5th International ATTR Amyloidosis Meeting for Patients and...
Announcement

Intellia Therapeutics Faces Class Action Lawsuit Amidst Declining Stock Performance

Published Fri, Apr 4 2025 7:02 PM UTC

In a notable development concerning the biotechnology sector, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is facing a class action securities lawsuit as announced by the law firm Levi & Korsinsky, LLP. The lawsuit, filed in a New York court, raises concerns about potential violations of securities laws by the company, prompting investors to rethink their positions in the stoc...
Stock Market Announcement

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Published Thu, Apr 3 2025 8:01 PM UTC

Intellia Therapeutics: Strategic Inducement Grants Fuel Growth in CRISPR Gene Editing InnovationIntellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in gene editing through CRISPR-based therapies, continues to bolster its workforce by granting inducements to new hires. The company awarded inducement grants under the Nasdaq Listing Rule 5635(c)(4) as a part of its strategy ...
Announcement

Intellia Therapeutics Navigating Investor Rights Amid Financial Triumphs and Legal Challenges

Published Sun, Mar 30 2025 5:30 AM UTC

In the fast-paced world of biotechnology, the importance of protecting investor interests cannot be overstated. As the landscape shifts with breakthrough research and corporate developments, the cautionary tales of missteps and missed opportunities proliferate. In this regard, Rosen Law Firm, a respected global investor rights law firm, is sounding the alarm for those who ha...
Announcement

Intellia Therapeutics Faces Legal Scrutiny as Revenue Growth Lags Behind Competitors

Published Fri, Mar 21 2025 5:41 PM UTC

In a landscape where innovative medical therapeutics often drive market excitement, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is currently navigating both financial headwinds and potential legal challenges. Rosen Law Firm, a prominent global investor rights law firm, has recently issued a reminder to those who purchased Intellia securities between July 30, 2024, and January...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 28.33
Price to Sales (Expected) -
Price to Book 2.32
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.51
Working Capital Ratio 6.65
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.41 $
Revenues (TTM) 0.45 $
Cash Flow (TTM) -
Cash 3.28 $
Book Value 5.45 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 157,841
Net Income per Employee (TTM) -1,060,942
Receivable Turnover Ratio (TTM) 6.44
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.07

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -1472.25 %
Net Margin (MRQ) -1392.27 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Intellia Therapeutics Inc's Segments
Member    296.47 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.